05:28 AM EDT, 08/20/2025 (MT Newswires) -- (Updates with the stock move in the headline and the first paragraph.)

Alcon ( ALC ) shares were 10% lower in Wednesday's premarket activity after the eye care firm reported Q2 sales below market expectations and lowered its outlook for full-year 2025 revenue, taking the shine out of its Q2 earnings beat.

The company reported Q2 core earnings late Tuesday of $0.76 per diluted share, up from $0.74 a year earlier.

Analysts polled by FactSet expected $0.72.

Net sales for the quarter ended June 30 were $2.58 billion, up from $2.48 billion a year earlier.

Analysts surveyed by FactSet expected $2.62 billion.

The company reiterated its full-year 2025 core EPS guidance of $3.05 to $3.15. Analysts surveyed by FactSet expect $3.12.

The company now expects 2025 revenue of $10.3 billion to $10.4 billion, versus $10.4 billion to $10.5 billion earlier. Analysts surveyed by FactSet expect $10.47 billion.

Alcon ( ALC ) said it launched Tryptyr for dry eye disease in the US. It also agreed to acquire STAAR Surgical to expand its presence in myopia correction. Financial details of the deal were not disclosed.